Oruka Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 13, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 13, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
Trading Plans
During the quarter ended March 31, 2026, no director or Section 16 officer adopted orterminated any Rule 10b5-1 trading arrangements or non-Rule 10b5-1 trading arrangements (in each case, as defined in Item 408(a) of Regulation S-K), except as disclosed below.
On February 11, 2026, Arjun Agarwal, our Senior Vice President – Finance and Treasurer, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of shares of our common stock over a period ending upon the earlier of when all shares under the plan are sold, or February 26, 2027, subject to certain conditions. This plan covers the sale of up to (i)97,965 shares (ii) 100% of net vested RSUs from gross RSU grants of up to 4,375 shares and (iii) 100% of shares purchased pursuant to the ESPP on June 8, 2026 and December 8, 2026.
On February 19, 2026, Carl Dambkowski, adirector in our company, adopted a Rule 10b5-1 trading arrangement intended to satisfy the affirmative defense of Rule 10b5-1(c) for the sale of up to 140,000 shares of our common stock over a period ending upon the earlier of when all shares under the plan are sold, or May 31, 2027, subject to certain conditions.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.